Hippocampal gene expression dysregulation of Klotho, nuclear factor kappa B and tumor necrosis factor in temporal lobe epilepsy patients

Marcelo Ananias Teocchi¹, Ana Érika Dias Ferreira¹, Evandro Pinto da Luz de Oliveira², Helder Tedeschi² and Lilia D'Souza-Li¹*

Abstract

Background: Previous research in animal seizure models indicates that the pleiotropic cytokine TNF is an important effector/mediator of neuroinflammation and cell death. Recently, it has been demonstrated that TNF downregulates Klotho (KL) through the nuclear factor kappa B (NFkB) system in animal models of chronic kidney disease and colitis. KL function in the brain is unclear, although Klotho knockout (KL⁻⁻) mice exhibit neural degeneration and a reduction of hippocampal synapses. Our aim was to verify if the triad KL-NFkB1-TNF is also dysregulated in temporal lobe epilepsy associated with hippocampal sclerosis (TLE(HS)) patients.

Findings: We evaluated TNF, NFkB1 and KL relative mRNA expression levels by reverse transcription quantitative PCR (RT-qPCR) in resected hippocampal tissue samples from 14 TLE(HS) patients and compared them to five post mortem controls. Four reference genes were used: GAPDH, HPRT1, ENO2 and TBP. We found that TNF expression was dramatically upregulated in TLE(HS) patients (P <0.005). NFkB1 expression was also increased (P <0.03) while KL was significantly downregulated (P <0.03) in TLE(HS) patients. Hippocampal KL expression had an inverse correlation with NFkB1 and TNF.

Conclusions: Our data suggest that, similar to other inflammatory diseases, TNF downregulates KL through NFkB in TLE(HS) patients. The remarkable TNF upregulation in patients is a strong indication of hippocampal chronic inflammation. Our finding of hippocampal KL downregulation has wide implications not only for TLE(HS) but also for other neuronal disorders related to neurodegeneration associated with inflammation.

Keywords: Seizures, Hippocampal sclerosis, Neuroinflammation, TNF, KL, NFkB1, GFAP, Reference genes, Calcium homeostasis

Introduction

Temporal lobe epilepsy (TLE) is the most treatment resistant (refractory) partial epilepsy and only 20% of patients achieve seizure control with antiepileptic drugs (AEDs) [1]. Hippocampal sclerosis (HS) is the main pathological finding observed in excised tissue from TLE patients treated with amygdalohippocampectomy. Only 10% of TLE patients with HS, who are treated with AEDs, become seizure-free which emphasizes the importance of HS as a prognostic factor [1]. HS is characterized by an abnormal increase in the number of astrocytes associated with the destruction of nearby neurons (astrogliosis) [2]. One of the primary events in seizure-induced cell death in the hippocampus is the excessive release of glutamate with consequent overload in intracellular calcium influx [3]. Within the neuronal cells, sophisticated homeostatic mechanisms control calcium levels. Altered Ca²⁺ sensitivity or defective Ca²⁺ regulation appear to be involved in the aging process, contributing to the progressive neurodegeneration in Alzheimer's disease and the intensified susceptibility to cell death after a seizure or stroke [3,4].
Klotho (KL), originally identified as an anti-aging protein, is involved in multiple functions in many systems and acts as an important calciphorempolysregulatory hormone [5]. KL mRNA is expressed only in limited organs, that is the brain, kidney, reproductive organs, pituitary gland and parathyroid glands [6,7]. Its cerebral function is unclear, however Klotho knockout (KL−/−) mice exhibit a phenotype resembling human aging, showing neural degeneration and a reduction of synapses in the hippocampus [6]. In addition, KL regulates the cellular lifespan of human cells by repressing the pro-apoptotic tumor protein p53 (TP53) [8], which regulates a number of apoptosis-related genes.

Important components and features of medial TLE, such as hippocampal intracellular calcium imbalance, neurodegeneration, hippocampal atrophy and cognitive decline, led us to question whether KL would also be downregulated in temporal lobe epilepsy associated with hippocampal sclerosis (TLE(HS)) patients. Furthermore, several studies assert that inflammation has a crucial role in epileptogenesis [9] and an increasing body of evidence connects astroglialis to neuroinflammation [10]. In epilepsy, the pleiotropic cytokine TNF is indicated as being an important effector/mediator of neuroinflammation and cell death [9,11-15]. Interestingly, it has been demonstrated that TNF downregulates KL through the transcription nuclear factor kappa B (NFkB) in animal models of chronic kidney disease and colitis [16,17]. Since inflammation and neurodegeneration seem to be connected in HS, our objective was to verify if the triad KL-NFKB1-TNF is also dysregulated in TLE(HS).

Methods
Ethical approval was certified by the “Comitê de Ética da Faculdade de Ciências Médicas da Unicamp (CEP n 470/2003)”.

Patients, post mortem controls and tissues
Electroencephalogram (EEG) video monitoring/telemetry was performed on all patients to confirm the onset of seizure in the medial temporal lobe. Dual pathologies or multifocal epilepsies were not identified. Hippocampal atrophy was detected by magnetic resonance imaging (MRI) in all patients.

Each patient signed an informed consent agreement to allow scientific use of the tissue. All procedures were carried out with the approval of the local research ethics committee, and in compliance with institutional guidelines and relevant laws.

Fourteen TLE(HS) patients had the amygdalohippocampectomy procedure performed for therapeutic reasons (Table 1). Hippocampal tissue samples from all 14 patients were immediately collected and divided into two parts. One portion was immediately snap-frozen in liquid nitrogen and stored at −80°C until RNA isolation occurred. The second portion was fixed for histopathological analysis and HS was confirmed in all of them.

Five post mortem control hippocampal tissue samples (one female, four males; 28.2 ± 13.1 years; range from 19 to 50 years old) were provided by the Instituto Médico Legal (IML) de Campinas. Despite some traumatic deaths, no neurological abnormalities were detected. Subjects passed away unexpectedly and instantly, which minimizes...
the occurrence and progression of neuroinflammation. The post mortem delay averaged 7.8 hours (range from 6 to 9 hours).

RNA extraction and reverse transcription quantitative PCR (RT-qPCR)
To extract total RNA, 1 ml of TRIzol Reagent (Life Technologies, Foster City, CA, USA) was added per 75 mg of frozen tissue samples, homogenized and then further processed according to the manufacturer’s instructions. The RNA integrity number (RIN) mean in both the control and patient groups was similar: 6.68 ± 0.9441 (n = 5) and 6.155 ± 0.2484 (n = 11), respectively. Due to the fact that the RNA was unavailable, the RIN was not evaluated for three patient samples: TLE 03, TLE 11 and TLE 13. Subsequently, 1 μg of total RNA of each sample was reverse transcribed into cDNA using 200 U of Superscript III Reverse Transcriptase (Life Technologies) and 3 μg of Random Primers (Life Technologies) according to the manufacturer’s instructions.

Sterilized and filtered DEPC-treated water was used in all cDNA synthesis reactions. Complementary DNA samples derived from the investigated genes were detected using an ABI PRISM 7500 Sequence Detection System (Life Technologies) and TaqMan Gene Expression Assays (Life Technologies): 5′-FAM-labeled probes and corresponding primer pairs (Table 2). Gene names are in accordance with the approved symbol from the HUGO Gene Nomenclature Committee (HGNC) database. To select the reference genes (endogenous controls), the study of Wierschke et al. on human epileptogenic tissues was considered [18]. Among 12 candidate genes, the algorithm NormFinder indicated hypoxanthine phosphoribosyltransferase 1 (HPRT1), enolase 2 (gamma, neuronal) (ENO2) and TATA box binding protein (TBP) as good normalization factors, since as single genes their expression levels were among the five most stable. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a very often used reference gene, showed a relatively unstable expression. However, to reinforce our results, we opted to test all four reference genes. Glial fibrillary acidic protein (GFAP) was used as an upregulation control [18-20]. Each qPCR was run as triplicates with 10 ng cDNA sample in 6.25 μl TaqMan Gene Expression Master Mix (Life Technologies), 0.625 μl of the respective probe/primer mix, and 0.625 μl purified and deionized H2O.

The amplification of all samples was of the same efficiency for precise quantification of reverse transcription quantitative PCR (RT-qPCR) data. Serial fivefold dilutions, starting with 250 ng of cDNA from the RNA quantification, of a cDNA solution pooled from the control group was used. The mean C_T values, measured in triplicates, versus the log10 of the dilution was plotted. The values from linear regressions applied to these plots were also presented (not shown). The amplification efficiencies (E = 10(−1/slope)) were close to 1.0 (100%).

Data analysis
Relative gene expression quantification data was generated and analyzed using the 7500 Software version 2.0.5 (Life Technologies). One of the post mortem control samples was randomly chosen as the benchmark and the quantification data from the other samples, including controls and patients, was evaluated according to this reference sample, which always had a relative quantification of 1.0. This allowed the two groups (post mortem controls and TLE(HS) patients) to be statistically compared.

The GraphPad Prism 5 software version 5.04 for Windows was used for the statistical analysis (San Diego, CA, USA; www.graphpad.com). The Mann–Whitney U test was used for comparison between data from the control group (n = 5) versus the patient group (n = 14). All comparison data are presented as mean and SD. Correlation among the target genes was performed by the Spearman’s rank correlation (Spearman’s R). The

Table 2 Genes and gene expression assays analyzed in this study

| Gene symbol | Name | Task | TaqMan Assay number | Amplicon (bp) | Slope | R² | Efficiency |
|-------------|------|------|---------------------|--------------|-------|-----|------------|
| ENO2        | Enolase 2 (gamma, neuronal) | Reference gene | Hs00157360_m1 | 77 | 3.356 | 0.994 | 98.61 |
| GAPDH       | Glyceraldehyde-3-phosphate dehydrogenase | Reference gene | 4333764 F | 122 | 3.313 | 0.996 | 100.36 |
| GFAP        | Glial fibrillary acidic protein | Upregulation marker | Hs00909236_m1 | 59 | 3.414 | 0.999 | 96.29 |
| HPRT1       | Hypoxanthine phosphoribosyltransferase 1 | Reference gene | 4333768 F | 100 | 3.306 | 0.988 | 100.67 |
| KL          | Klotho | Target | Hs00183100_m1 | 74 | 3.396 | 0.998 | 97.02 |
| NFKB1       | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | Target | Hs00765730_m1 | 66 | 3.388 | 0.997 | 97.30 |
| TBP         | TATA box binding protein | Reference gene | Hs99999910_m1 | 127 | 3.407 | 0.993 | 96.57 |
| TNF         | Tumor necrosis factor | Target | Hs99999043_m1 | 85 | 3.266 | 0.991 | 102.39 |
reference sample was excluded from correlation tests and differences of \( P < 0.05 \) were considered significant.

**Results and discussion**

The quality of the RNA and the reliability of reference genes to quantify gene expression in surgical tissue are crucial in interpreting epilepsy-related changes of gene expression [18,21]. The similarity in the RIN average between TLE patients and the control group (6.68 ± 0.9441 and 6.155 ± 0.2484, respectively) reinforces our results. *Post mortem* delay has always been considered a major factor when interpreting the accuracy of results from human tissue studies; however, this may not be a factor for human brain RNA [21]. Durrenberger *et al.* concluded that *post mortem* delay caused only a minor deterioration and had no effect on RNA quality. The same results were found in previous research mentioned in their report [21]. We worked with a *post mortem* delay of between 6 to 9 hours, which would not seem to contradict the findings of the Durrenberger study.

Our results (Figure 1) showed a dramatic increase on TNF relative mRNA expression in hippocampal tissue of TLE(HS) patients in comparison with the *post mortem* controls (\( P < 0.005 \), regardless of the reference gene). Despite the same \( P \) value for the results regarding the four reference genes used, the TNF expression mean in patients had an ample variation: from 29.61 ± 8.55 (TBP) to 110.4 ± 58.82 (HPRT1). The combination of ENO2 and TBP as the normalization factor proved to be very stable in epileptogenic tissues [18]. Therefore, in Figure 2, we used this combination to show the relative TNF expression individually by subject.

Our data suggests that the marked TNF upregulation in patients’ tissues corroborates with the chronic hippocampal inflammation in TLE(HS). Table 1 shows that several patients had their last seizure several days before the surgery, suggesting that the high TNF expression levels were frequent, signaling that chronic hippocampal inflammation could be intrinsic to the refractory TLE(HS) syndrome. A number of studies in animal models indicate that seizures induce TNF expression in the brain [9,11-14]. Our findings confirm that a similar induction also occurs in TLE patients. However, despite the intense investigation of the TNF system and its effects in seizure models, there is not unanimous agreement on its effects in TLE(HS) and clinical studies are scarce [11]. Moreover, similar to recent findings on inflammatory disease models [16,17], our data indicates that the synthesis of KL is reduced in the sclerotic hippocampus and TNF may downregulate KL through NfkB in TLE(HS) (Figures 1 and 2).

While KL mRNA was significantly downregulated (HPRT1 and TBP; \( P < 0.001 \); GAPDH: \( P < 0.02 \); ENO2: \( P < 0.001 \); GAPDH: \( P < 0.02 \); ENO2: \( P < 0.001 \); HPRT1: \( P < 0.001 \); TBP: \( P < 0.001 \); Figure 1). Our data suggests that the marked TNF upregulation in patients’ tissues corroborates with the chronic hippocampal inflammation in TLE(HS). Table 1 shows that several patients had their last seizure several days before the surgery, suggesting that the high TNF expression levels were frequent, signaling that chronic hippocampal inflammation could be intrinsic to the refractory TLE(HS) syndrome. A number of studies in animal models indicate that seizures induce TNF expression in the brain [9,11-14]. Our findings confirm that a similar induction also occurs in TLE patients. However, despite the intense investigation of the TNF system and its effects in seizure models, there is not unanimous agreement on its effects in TLE(HS) and clinical studies are scarce [11]. Moreover, similar to recent findings on inflammatory disease models [16,17], our data indicates that the synthesis of KL is reduced in the sclerotic hippocampus and TNF may downregulate KL through NfkB in TLE(HS) (Figures 1 and 2).

While KL mRNA was significantly downregulated (HPRT1 and TBP; \( P < 0.001 \); GAPDH: \( P < 0.02 \); ENO2: \( P < 0.001 \); GAPDH: \( P < 0.02 \); ENO2: \( P < 0.001 \); HPRT1: \( P < 0.001 \); TBP: \( P < 0.001 \); Figure 1). Our data suggests that the marked TNF upregulation in patients’ tissues corroborates with the chronic hippocampal inflammation in TLE(HS). Table 1 shows that several patients had their last seizure several days before the surgery, suggesting that the high TNF expression levels were frequent, signaling that chronic hippocampal inflammation could be intrinsic to the refractory TLE(HS) syndrome. A number of studies in animal models indicate that seizures induce TNF expression in the brain [9,11-14]. Our findings confirm that a similar induction also occurs in TLE patients. However, despite the intense investigation of the TNF system and its effects in seizure models, there is not unanimous agreement on its effects in TLE(HS) and clinical studies are scarce [11]. Moreover, similar to recent findings on inflammatory disease models [16,17], our data indicates that the synthesis of KL is reduced in the sclerotic hippocampus and TNF may downregulate KL through NfkB in TLE(HS) (Figures 1 and 2).
<0.03), the expression level of NFKB1 was also augmented in patients (GAPDH, HPRT1, and ENO2: P <0.02; TBP: P <0.03) (Figure 1). It remains to be elucidated whether the KL depressed expression has a role in TLE(HS) physiopathology or is only a secondary change caused by the imbalance of calcium or phosphate and/or the progression of HS in the medial TLE syndrome. Since KL is a pleiotropic protein with different functions on many systems, our findings on KL downregulation opens up a gamut of study possibilities in HS pathophysiology comprehension.

We initially highlighted two specific functions assigned to KL: it has a stimulating effect on the Na⁺/K⁺ ATPase pump activity [22] and it influences the Wnt signal pathway [23]. Considering the importance of Na⁺/K⁺ ATPase activity in neuronal electrical activity and excitability [24], it is important to determine if KL regulates Na⁺/K⁺ ATPase in the hippocampus, which could be involved with the evident synaptic reduction found in Kl−/− mice [6,7]. The molecular mechanisms regarding the neurodegenerative feature found in Kl−/− mice and analogously to HS have not yet been elucidated. By acting on the Wnt signaling, KL offers an interesting outlook as it suppresses several Wnt family members [23]. It has been demonstrated that stimulation of Wnt signaling contributes to stem and progenitor cell senescence, and persistent decreased KL expression may affect the rate of cellular aging and have harmful impact on tissue repair mechanisms [17]. This could be a key factor in HS progression.

There is another connection between KL depression and astrogliosis. By suppressing TP53 and negatively regulating cyclin-dependent kinase inhibitor 1 (CDKN1A, also known as p21) protein levels, KL not only inhibits apoptosis but also modulates the lifespan of human cells, which may be associated with increased signaling through the insulin/insulin-like growth factor 1 (IGF-1) pathway [8]. This growth factor has a significant role in non-neuronal modulation and multiple reports have indicated that astrocytes are the main target of IGF-1 by regulating their response to tissue injury [25]. Since KL may inhibit the insulin/IGF-1 pathway [26], its downregulation could support astrogliosis by a detrimental effect on neurons and astrocyte proliferation. In fact, Kl−/− mice have neuronal cell degeneration with a drastic increase in GFAP levels [27]. As expected, GFAP was upregulated in patients (GAPDH, HPRT1, and ENO2: P <0.001; TBP: P <0.02), which supports astrogliosis (Figure 1).

Furthermore, KL has been considered an anti-inflammatory protein and this property could be one of its most striking features. In the endothelium, KL confers protection against nitric oxide (NO)-induced dysfunction [28], reduces the expression of adhesion molecules [28] and potentially regulates T cell functions [29]. In 2007, Witkowski et al. reported that KL was downregulated in CD4⁺ lymphocytes at the mRNA, protein and enzymatic (beta-glucuronidase) activity levels in healthy, older adults and especially in rheumatoid arthritis (RA) patients [29]. Regardless of the unclear link between KL activity and CD4⁺ cell function, they proposed that KL might be involved in physiological anti-inflammatory responses in young individuals, but these responses decreased in both healthy older adults and RA patients. Their hypothesis was supported by the fact that KL expression and activity reduction, in both older adults and RA patients’ lymphocytes, occurred in concert with the downregulation of CD28, a TNF-increased dependent T cell costimulatory molecule.

The Kl−/− mouse also exhibits atherosclerosis and endothelial dysfunction, which led Maekawa et al. [28] to test the effect of KL on vascular inflammation. KL suppressed the TNF-induced expression of adhesion molecules and NFκB activation in endothelial cells in vitro (human umbilical vein endothelial cells (HUVECs)) and ex vivo (organ culture of the rat aorta).
Moreover, KL reversed the repression of the nitric oxide synthase 3 (NOS3) phosphorylation by TNF and inhibited the TNF-induced monocyte adhesion to HUVECs. These results suggest that KL may have a function in the modulation of endothelial inflammation, especially by TNF-induced NFKB inhibition. Therefore, it is plausible that KL downregulation could further exacerbate the TLE(HS) associated chronic inflammatory condition.

Moreno et al. related that the inflammatory cytokines tumor necrosis factor ligand superfamily member 12 (TNFSF12, also known as TWEAK) and TNF downregulate KL in renal tubular cells through an NFkB-dependent mechanism mediated by histone deacetylase 1 (HDAC1) [16]. In this regard, we observed that the HDAC inhibitors trichostatin A (TSA) or valproic acid prevented repression of KL induced by TWEAK or TNF. Among the patients studied, only TLE 09 was taking valproate during the surgery and only TLE 06 took this medication in the past. We did not observe any particular difference in these patients compared with the others. KL expression was negatively correlated with NFKB1 or TNF expression, while the pair TNF and NFKB1 showed a positive correlation. This suggests that NkfB in patients is most likely modulated by TNF or even KL [28] and not by AEDs, although further studies are required to test the influence of AEDs in the gene expression of our targets. Gene expression data correlation was found in the three pairs tested: KL-NFkB (Spearman’s R = −0.3140; P = 0.0091), KL-TNF (Spearman’s R = −0.3283; P = 0.0063), and NFkB1-TNF (Spearman’s R = 0.4441; P = 0.0001).

In addition, Thurston et al. showed that in mouse models of inflammatory bowel disease the degree of KL inhibition was related to the severity of colitis and that attenuation of inflammation with a neutralizing anti-TNF antibody impeded this inhibition [17]. Furthermore, the neurodegenerative feature found in Kt−/− mice suggests that KL in the hippocampus may act as a protective autocrine hormone and its absence causes neuronal loss [30].

Our work on the mRNA level suggests that the triad KL-NFkB1-TNF is disrupted in the hippocampus from medically intractable TLE patients. Based on the KL function studies discussed here, we propose the first mechanistic insights into the role that this triad may play in the pathogenesis of medial TLE. It is conceivable that there is a major involvement of the KL-TNF axis in the pathogenesis of TLE(HS), particularly under chronic inflammatory conditions. Further research on the protein level will strengthen our results and the design of functional studies will be able to elucidate the role of our targets, especially KL, in the normal and pathological hippocampus. Due to the KL hormonal property [7,31] and TNF tissue diffusion as a cytokine [32,33], we believe that the epilepsy-associated inflammation is a widespread event in the hippocampus. Finally, since KL is detectable in cerebrospinal fluid [7,31,34], it is a potential candidate as an inflammatory biomarker in epilepsy. The inflammatory component of epilepsy is not a secondary phenomenon or complication of the pathology. It is more likely involved in the mechanisms that sustain neuronal hyperexcitability, the onset and recurrence of seizures, and progression and severity of the disease [15]. The determination of a reliable biomarker of brain inflammation is urgent, in view of the fact that a number of patients would benefit from an anti-inflammatory therapy.

Abbreviations
AED: antiepileptic drug; CBZ: carbamazepine; CDKN1A: cyclin-dependent kinase inhibitor 1 (p21 Cip1); DEPC: diethylpyrocarbonate; EEC: electroencephalogram; ENO2: enolase 2 (gamma neuronal); GAPDH: glyceraldehyde 3-phosphate dehydrogenase; GFAP: glial fibrillary acidic protein; HDAC1: histone deacetylase 1; HGNC: HUGO Gene Nomenclature Committee; HPRT1: hypoxanthine phosphoribosyltransferase 1; HS: hippocampal sclerosis; HUVEC: human umbilical vein endothelial cell; IGF-1: insulin-like growth factor 1 (somatomedin C); IML: Instituto Médico Legal; KL: Klotho; Kt−/−: Klotho knockout; LTG: lamotrigine; MR: magnetic resonance imaging; NFkB: nuclear factor kappa B; NFkB1: nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; NOS3: nitric oxide synthase 3 (endothelial cell); OXC: oxcarbazepine; PCR: polymerase chain reaction; PHT: phenytoin; RA: rheumatoid arthritis; RIN: RNA integrity number; RT-qPCR: reverse transcription quantitative PCR; TBP: TATA box binding protein; TLE: temporal lobe epilepsy; TLE(HS): temporal lobe epilepsy associated with hippocampal sclerosis; TNF: tumor necrosis factor; TNFSF12: tumor necrosis factor ligand superfamily member 12 (TWEAK); TP53: tumor protein p53; TSA: trichostatin A; VPA: valproic acid.

Competing interest
All authors declare that they have no competing interest.

Authors’ contributions
MAT designed the study, collected clinical data, performed the experiments, analyzed the data, prepared the figures and tables, and drafted the manuscript. AEDF collected clinical data and helped to perform the experiments. EPLO and HT are neurosurgeons and operated on patients. LD-L designed and coordinated the study and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This study was financially supported by the São Paulo Research Foundation (FAPESP; processo 05/56577-4) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). Quantitative PCRs were carried out in the Multuser Laboratory (www.laboratoriomultiusuario.com.br) and RIN detection was performed in the Central Laboratory of High Performance Technologies (LACTAD), www.lactadunicamp.br, both also supported by FAPESP. MAT wishes to thank David Elieff for helping with the English language review.

Author details
1Laboratory of Pediatric Endocrinology, Center for Investigation in Pediatrics, University of Campinas, PO Box 6111, Campinas, SP 13083-970, Brazil.
2Department of Neurology, Faculty of Medical Sciences, University of Campinas, PO Box 6111, Campinas, SP 13083-970, Brazil.

Received: 1 November 2012 Accepted: 19 March 2013
Published: 1 May 2013
References

1. Semah F, Picot MC, Adam C, Broglin D, Arzinioanoglou A, Bazin B, Cavalcanti D, Baulac M: Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998, 51:1236–1262.

2. Greenfield JG, Graham D, Lantos PL: Greenfield's Neuropathology, 6th edition. London: Arnold; 1997.

3. Delorenzo RJ, Sun DA, Deshpande LS: Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintenance of epilepsy. Pharmacol Ther 2005, 105:229–266.

4. Raza M, Deshpande LS, Blair RE, Carter DS, Sombati S, DeLorenzo RJ: Aging is associated with elevated intracellular calcium levels and altered calcium homeostatic mechanisms in hippocampal neurons. Neurosci Lett 2007, 418:77–81.

5. Huang CL, Moe OW: Klotho: a novel regulator of calcium and phosphorus homeostasis. Pflugers Arch 2011, 462:185–193.

6. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurokawayash I, Kaname T, Kume I, Iwasaki H, Iida A, Shiraiki-Iida T, Nishikawa S, Nagai R, Nabeshima Y: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 389:45–51.

7. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 389:45–51.

8. de Oliveira RM: Klotho RNAI induces premature senescence of human cells via a p53/p21 dependent pathway. FEBS Lett 2006, 580:573–578.

9. Ravizza T, Balossio S, Vezzani A: Inflammation and prevention of epileptogenesis. Neurosci Lett 2011, 497:223–229.

10. Foresti ML, Alli GM, Shapira LA: Role of glia in epilepsy-associated neuropathology, neuroinflammation and neurogenesis. Brain Res Rev 2011, 66:115–122.

11. Li G, Bauer S, Nowak M, Norwood B, Tackenberg B, Rosenow F, Knake S, Oertel WH, Hamer HM: Cytoines and epilepsy. Seizure 2011, 20:249–256.

12. Plata-Salaman CR, Ilyin SE, Turrin NP, Gayle D, Flynn MC, Romanovitch AE, Kelly ME, Bureau Y, Anisman H, McIntyre DC: A novel regulator of calcium and phosphorus homeostasis. Cell Struct Funct 2004, 29:565–660.

13. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

14. Vezzani A, Friedman A: Emerging roles of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

15. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

16. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

17. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

18. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

19. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

20. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

21. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

22. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

23. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

24. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

25. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

26. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

27. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

28. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

29. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

30. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

31. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

32. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

33. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

34. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

35. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

36. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

37. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

38. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

39. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

40. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.

41. Vezzani A, Friedman A: Neurological impact of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. J Neurosci 2012, 32:607–614.